Ronald M. Bukowski Livres

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Biology of Renal Cell Carcinoma presents the proceedings of the Third International Symposium on the Biology of Renal Cell Carcinoma, March 1994. This symposium gathers 'internationally acclaimed researchers from relevant fields of renal cell carcinoma to present their latest work and to interact on the interpretation of these findings and direction for subsequent studies. The program is directed to physicians and research scientists involved in the clinical and basic research aspects of the treatment of renal cell carcinoma.' (from the Symposium Announcement) Topics covered in the areas of Molecular Biology of Renal Cell Carcinoma: Cytogenetics, Genetic Approaches to Therapy of Renal Cell Carcinoma, Immunology of Renal Cell Carcinoma - T-Cell Anergy, New Approaches with Renal Cell Carcinoma - Cytokines.